Oral Fosfomycin Treatment for Enterococcal Urinary Tract Infections in a Dynamic <i>In Vitro</i> Model
Iain J. Abbott, Elke van Gorp, Aart van der Meijden, Rixt A. Wijma, Joseph Meletiadis, Jason A. Roberts, Johan W. Mouton, Anton Y. Peleg
Abstract
There are limited treatment options for enterococcal urinary tract infections, especially vancomycin-resistant Enterococcus (VRE). Oral fosfomycin is a potential option, although limited data are available guiding dosing and susceptibility. We undertook pharmacodynamic profiling of fosfomycin against E. faecalis and E. faecium isolates using a dynamic in vitro bladder infection model. Eighty-four isolates underwent fosfomycin agar dilution susceptibility testing ( E. faecalis MIC 50/90 32/64 μg/ml; E. faecium MIC 50/90 64/128 μg/ml).
Topics & Concepts
FosfomycinUrinary systemEnterococcusIn vitroMicrobiologyEnterococcus faecalisMedicineAntibioticsBiologyEscherichia coliInternal medicineBiochemistryGeneUrinary Tract Infections ManagementEnterobacteriaceae and Cronobacter ResearchInfectious Disease Case Reports and Treatments